Literature DB >> 23294348

Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors.

Timo Heinrich1, Jeyaprakashnarayanan Seenisamy, Lourdusamy Emmanuvel, Santosh S Kulkarni, Jörg Bomke, Felix Rohdich, Hartmut Greiner, Christina Esdar, Mireille Krier, Ulrich Grädler, Djordje Musil.   

Abstract

Focal adhesion kinase (FAK) is considered as an attractive target for oncology, and small-molecule inhibitors are reported to be in clinical testing. In a surface plasmon resonance (SPR)-mediated fragment screening campaign, we discovered bicyclic scaffolds like 1H-pyrazolo[3,4-d]pyrimidines binding to the hinge region of FAK. By an accelerated knowledge-based fragment growing approach, essential pharmacophores were added. The establishment of highly substituted unprecedented 1H-pyrrolo[2,3-b]pyridine derivatizations provided compounds with submicromolar cellular FAK inhibition potential. The combination of substituents on the bicyclic templates and the nature of the core structure itself have a significant impact on the compounds FAK selectivity. Structural analysis revealed that the appropriately substituted pyrrolo[2,3-b]pyridine induced a rare helical DFG-loop conformation. The discovered synthetic route to introduce three different substituents independently paves the way for versatile applications of the 7-azaindole core.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23294348     DOI: 10.1021/jm3016014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

2.  FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

Authors:  Isabelle Tancioni; Sean Uryu; Florian J Sulzmaier; Nina R Shah; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Kristy K Ward; David D Schlaepfer
Journal:  Mol Cancer Ther       Date:  2014-06-04       Impact factor: 6.261

Review 3.  Targeting FAK in human cancer: from finding to first clinical trials.

Authors:  Vita M Golubovskaya
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

4.  Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.

Authors:  Brian J Groendyke; Behnam Nabet; Mikaela L Mohardt; Haisheng Zhang; Ke Peng; Eriko Koide; Calvin R Coffey; Jianwei Che; David A Scott; Adam J Bass; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2020-12-14       Impact factor: 4.345

5.  Scope and limitations of a DMF bio-alternative within Sonogashira cross-coupling and Cacchi-type annulation.

Authors:  Kirsty L Wilson; Alan R Kennedy; Jane Murray; Ben Greatrex; Craig Jamieson; Allan J B Watson
Journal:  Beilstein J Org Chem       Date:  2016-09-08       Impact factor: 2.883

Review 6.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

7.  Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors.

Authors:  Alan Jiang; Qiufeng Liu; Ruifeng Wang; Peng Wei; Yang Dai; Xin Wang; Yechun Xu; Yuchi Ma; Jing Ai; Jingkang Shen; Jian Ding; Bing Xiong
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

Review 8.  Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.

Authors:  Marina Roy-Luzarraga; Kairbaan Hodivala-Dilke
Journal:  Clin Cancer Res       Date:  2016-06-04       Impact factor: 12.531

Review 9.  FAK inhibitors as promising anticancer targets: present and future directions.

Authors:  Muhamad Mustafa; Amer Ali Abd El-Hafeez; Dalia A Abdelhafeez; Dalia Abdelhamid; Yaser A Mostafa; Pradipta Ghosh; Alaa M Hayallah; Gamal El-Din A Abuo-Rahma
Journal:  Future Med Chem       Date:  2021-08-03       Impact factor: 4.767

Review 10.  Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.

Authors:  Rayan Naser; Abdullah Aldehaiman; Escarlet Díaz-Galicia; Stefan T Arold
Journal:  Cancers (Basel)       Date:  2018-06-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.